VVOS Vivos Therapeutics Inc.: Debt to Equity

Vivos Therapeutics (VVOS) develops innovative sleep apnea solutions, leveraging partnerships with dental laboratories while maintaining full patent ownership. This price chart, illustrating changes in the total debt-to-equity ratio—which currently stands at 0.00—links concerns over expensive marketing and slow product adoption with growth potential driven by new FDA approvals and an expanding physician base.

Vivos Therapeutics (VVOS) maintains strong pricing power in the production of apnea treatment equipment, enabling the generation of a stable cash flow that dictates its development financing strategy. The total liabilities-to-equity ratio measures the business's reliance on external borrowing, while the debt-to-equity trend helps investors assess the balance between investment risk and the management's financial stability.